introduction Sunitinib and pazopanib are vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) with proven efficacy in the first line in metastatic clear cell renal cancer (mRCC) [1, 2] . A recent study established these two agents as standard therapy in this setting [3] . Both agents are associated with significant toxicity. Therefore, cessation of treatment after patients have achieved an initial benefit is potentially attractive and under investigation in clinical trials (NCT06473203). Intermittent therapy is widely given in other tumours, and retrospective data from highly selected renal cancer patients suggest that treatment breaks after complete remission with sunitinib may be safe [4] .
However, a potential concern of this approach originates from preclinical data, which suggest that the cessation of treatment may accelerate tumour growth and metastatic development [5] . Rapid onset of angiogenesis has been observed in nephrectomy specimens following treatment interruption in humans [6] . Furthermore, acceleration of tumour growth during the 2-week treatment break with sunitinib has been reported in the clinical setting [7] . It is conceivable that VEGF TKI therapy results in dynamic molecular changes associated with accelerated tumour growth, which becomes clinically apparent, in the form of rapid progression when VEGF-targeted therapy is stopped. It is unclear if reintroduction of targeted therapy after progression during a treatment break can halt or reverse this process.
To investigate the significance of cessation of therapy, we analyses the results of three almost identical prospective phase II clinical trials, all of which has a structured treatment interruption [8] [9] [10] . In these studies, patients received a period of VEGF TKI therapy (12-16 weeks) prior to a planned treatment interruption (4-5 weeks) for debulking nephrectomy. Patients then restarted the same targeted therapy irrespective of the occurrence of progression. The frequency and significance of progression in the peri-operative treatment break was assessed. Functional imaging was performed before and after the treatment break to assess dynamic changes to the tumour during this period.
materials and methods patients
Patients included in this analysis originated from three independent, singlearm phase II studies, two using sunitinib and one pazopanib. All three studies investigated targeted therapy prior to planned nephrectomy in biopsy-proven mRCC. Patients included signed written informed consent. The significance of the treatment break on progression was a second endpoint of the studies.
The studies had very similar inclusion criteria: two of the studies investigated sunitinib [50 mg orally (PO) once daily (OD) 4/2 weeks] for 12-16 weeks prior to nephrectomy, while the final study investigated pazopanib (800 mg PO OD) for 12-14 weeks prior to planned nephrectomy. Both sunitinib studies are completed and published while the pazopanib study has reached interim analysis that has been presented [8] [9] [10] .
Each of the three studies has an enforced treatment break during the time of the nephrectomy to allow for wound healing. The treatment break was planned for between 4 and 5 weeks. All patients who restarted TKI therapy recommenced on the same agent as they had pre-nephrectomy. In total, 98 patients have been enrolled in these studies. A number of patients enrolled in the studies were not included in this second analysis as they did not have a nephrectomy and therefore, there was no planned treatment break ( Table 1 ). The reason for this was disease progression prior to planned surgery by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (n = 20), co-morbidity (n = 2), patient choice not to undergo surgery despite clinical benefit (n = 9) and patients not recommencing VEGF TKI therapy within 6 weeks (n = 5). Therefore, 62 of 98 evaluable patients restarted TKI therapy post-nephrectomy with no evidence of progression of disease during pre-nephrectomy systemic therapy. The median duration of this treatment break was 4.3 (range: 3.4-6) weeks.
radiological assessment
All patients were assessed according to RECIST v1.1. Computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis were performed. Scanning occurred at baseline and prior to nephrectomy. Radiological assessment occurred after the enforced treatment break (4-6 weeks post-surgery). The pre-operative and postoperative scans were compared. This separated patients into two groups ( progressors and non-progressors). Patients were subsequently followed up with regular imaging (12 weekly), and survival was analysed using the Kaplan-Meier method. Due to treatment-access issues in the UK and Netherlands at the time of the trial, only 17% received second-line therapy. Radiological analysis took place centrally (IK). F-fluorodeoxyglucose positron emission tomography (FDG-PET) CT scans were performed in 24 patients as part of a translational sub-study. Scans were performed at baseline, pre-surgery and post-surgery. All patients had restarted targeted therapy for a median time of 4 weeks when the final scan was performed. Previous analysis has established that 92% of patients with mRCC are PET-positive [standard uptake variable (SUV) <2.5] responses (25% reduction in SUV) after 4 weeks of therapy occurs in 57% of patients [11] . Analysis of the scans was performed to explore the FDG-PET progression (25% increase in SUV or new positive lesions [standard uptake variable (SUV) <2.5] during the treatment break by comparing the pre and post-surgery scans. Analysis took place centrally (IK).
functional imaging analysis

statistical analysis
Landmark analysis was performed at the time of the post-treatment scan to separate patients into progressors and non-progressors. Descriptive statistics were used to compare patients and groups. PFS and overall survival were estimated using the Kaplan-Meier method. Specific factors were analysed for prognostic significance by univariate and multivariate Cox regression analyses. This analysis was performed at the time of the post-operative CT scan. These studies and subsequent analysis had appropriate ethical approval.
results
The patient's characteristics are shown in Table 1 ; column 1 includes all patients recruited to the three clinical trials (N = 98) and column 2 shows the characteristics of patients that had stable disease prior to nephrectomy and restarted VEGF TKI therapy post-nephrectomy within 6 weeks (n = 62). The median overall survival of these 62 patients from the time of the posttreatment scan was 23.5 months (95% CI: 15.2-NA). Of those 62 patients, 23 (37%) progressed by RECIST v1.1 on the first scan after the treatment break (performed a median of 6.3 weeks after nephrectomy). This rate of progression was higher than that seen in scans performed at other time points ( Figure 1A) . The progressors and non-progressors have similar baseline characteristics, such as Memorial Sloan Kettering Cancer Centre (MSKCC) prognostic group and initial response therapy ( Table 1 ). The only factor that was different between the two groups was the progressors had a higher Furman grade at nephrectomy. This may represent more aggressive biology of the disease in the progressors. Unfortunately, patients do not routinely have surgery prior to a treatment break making the utility of this data limited.
Multivariate analysis performed at the time of the postnephrectomy scan revealed that progression during the treatment break was associated with a significantly shorter overall survival (hazard ratio [ Of the 23 patients with progression during the peri-operative treatment break, 17 (77%) had new sites of disease. The commonest sites of progression were lung (11), lymph node (5), liver (5), bone (3), brain (2) and other (4) . Sixteen (70%) of the 23 patients who restarted drug with progression had stable disease or better on the subsequent CT (13 patients has 
CT and FDG-PET findings
Sequential FDG-PET CT scans were performed at baseline, after three cycles of sunitinib therapy and 6 weeks after surgery in 24 of the 62 nephrectomy patients described in Table 1 . The CT and FDG-PET findings on these target lesions were compared. Systemic therapy was associated with a significant decrease in the size of the lesions on CT (n = 144; 23% decrease) and SUV (n = 122; 59% decrease) [P < 0.05 for each]. During the treatment break, there was no significant increase in size (median increase 9%), but a significant increase in SUV (34%) (Figure 1B-D) . Five patients did not restart TKI therapy. This was due to delayed wound healing (n = 1), prolonged post-operative recovery (n = 2) patient choice (n = 1) and post-operative death (n = 1). **P < 0.05. The relationship between the change in metabolic activity and size was examined (n = 122). There was a significant correlation between the change in size and SUV (r = 0.72; P < 0.001).
discussion
In this analysis, we demonstrate that a planned treatment interruption of approximately 4 weeks, after 12-16 weeks of Figure 1. (A) The timing of the progression of disease. The specific CT scans responsible for identifying the progression of disease by RECIST v1.1. Presurgery CT occurred 0-2 weeks pre-surgery, and post-surgery CT occurred 4-6 weeks post-surgery, subsequent imaging took place on a 12-week basis. The population at the risk of progression at the four scans was n = 90, n = 62, n = 40 and n = 34, respectively. (B) Cross-sectional imaging changes with therapy and during the treatment break. All CT measurable lesions (n = 144) and targeted lesions were followed. There was a significant decrease (23%: P < 0.01) in the lesions size with therapy, but no significant increase (9%; P = 0.13) during the treatment break. Wilcox and signed-rank test. (C) SUV changes with therapy and during the treatment break. All measurable SUV-positive lesions (n = 122) were followed. Results show a significant fall in SUV (59%: P < 0.01) after the initiation of therapy and a significant rise in SUV (34% P = 0.01) after the treatment interruption. Wilcox and signed-rank test. (D) Three sequential FDG-PET CT scans performed on the same patients. The baseline scan was 48 h prior to sunitinib. Post cycle 3 was 2 days after the completion of the third 28 day cycle. Post-surgery was 6 weeks after the surgery. The patients had been back on sunitinib for a period of 4 weeks. The images shows an initial response to the chest wall lesion (decrease SUV <25%) followed by progression after the treatment break. VEGF TKI therapy, is associated with rapid tumour progression at metastatic sites in a large proportion of patients. This progression is associated with an increased risk of death in multivariate analysis, despite the reintroduction of therapy regaining control of disease in 70% of patients. This finding appears to hold even in those patients who have initially responded to targeted therapy and is irrespective of sites of disease and other established prognostic factors, such as the MSKCC prognostic score. This suggests that progression during treatment cessation is not simply a marker for patients with a known poor prognosis at baseline. It also shows that it is not possible to select the subgroups of patients who are at a lower risk of this progression. The comparatively high frequency of progression (37%) during the treatment break ( Figure 1A) suggests that the occurrence is partly due to the break itself and does not simply reflect the normal course of disease while on treatment. This is supported by the observation that a high proportion of patients achieve disease control when the same VEGF TKIs are reintroduced, and that reported progression rates postnephrectomy in treatment naïve patients are significantly lower in other studies (9-12%) [12, 13] . Subset analysis was not able to identify the subgroups of patients who were likely to progress during the treatment break using clinical characteristics. Specifically, established prognostic factors, such as MSKCC prognostic score or initial response to therapy, were not able to identify these patients. This suggests that the observed progression during the treatment break is not simply the identification of patients with more aggressive disease at baseline and that VEGF TKI may have molecularly altered the tumours characteristics. Clinical data from sequential tissue samples suggest that this dynamic change to biology does occur [14] . Further molecular investigation of tissue from patients with acquired resistance may allow us to identify the mechanism of treatment failure.
Therefore, without clinical indicators identifying patients with an increased risk of progression, cessation of therapy should be approached with caution outside of the context of a clinical trial.
The clinical applicability of the data is limited as it is not currently routine practice to terminate targeted therapy in metastatic disease. Importantly, data may have implications in both the neoadjuvant and adjuvant setting. Our clinical data build on the preclinical models, showing that cessation of VEGF TKI therapy is associated with tumour acceleration, metastasis and more rapid death [5] . These data are only partially applicable as dosing and cell lines are not consistent with renal cancer [15] . It is noteworthy that new sites of disease occurred in 77% of our patients with progression, which support the theory of increased metastatic potential.
Other relevant work on renal cancer tissue shows an increase in angiogenic potential in pre-treated human tissue after cessation of TKI treatment [6] . The hypothesis that this relatively short VEGF TKI treatment break can alter tumour biology and rapid onset angiogenesis is supported by our functional imaging data, which showed a significant increase in SUV during this treatment break. Progression of disease with FDG-PET is of prognostic significance in metastatic renal cancer, and the changes observed add weight to the theory that the tumours are becoming more active during the break [11] . Whether these observations are a true reflection of changing biology of the disease cannot be ascertained without sequential tissue and a randomised trial. It is feasible that, despite our findings and the associated preclinical work, the observed tumour rebound is purely a refection of normal tumour regrowth. Further translational studies will explore this issue further.
The EFFECT trial, which compared standard (4 weeks on 2 weeks off ) sunitinib with continuous therapy (at 37.5 mg), showed that short breaks of 2 weeks do not adversely affect outcome [16] . Other retrospective data suggest that prolonged cessation of therapy may be considered in individuals who achieve a complete remission with VEGF TKI, although the majority of patients do ultimately progress with a significant number developing new metastatic sites [4, 17] . These data appear to contradict our findings. However, it is very likely that these retrospective series, with a high proportion of complete responders, are compiled of selected patients with a favourable biology. Recent randomised phase III data show that switching away from VEFG-targeted therapy in patients with sunitinib resistance has a shorter survival, supporting our findings [18] . Overall our data, from three controlled prospective trials, challenge the hypothesis that treatment breaks are safe in unselected patients. This work has a number of shortcomings. First, the trials were not randomised. Therefore, it is not possible to quantify the effect of the treatment break progression on overall treatment outcomes. The randomised phase III study European Organisation for Research and Treatment of Cancer (SURTIME) (testing upfront versus delayed nephrectomy) and the STAR study (NCT06473203) have the opportunity to validate these findings. All patients also presented with untreated metastatic disease with the primary tumour in situ, which may be unrepresentative of the metastatic RCC population as it excluded patients with metachronous metastases-a subgroup with relatively good prognosis. Finally, the endpoint was exploratory for all three prospective trials and, although very similar in design, the trials were not initially designed to be combined. Finally, FDG-PET scans were not available for all patients.
This work supports in vivo studies and, to our knowledge, is the first clinical data to question intermittent VEGF-targeted therapy. It supports the hypothesis that continued VEGFtargeted therapy is required to maximise survival [18] . 
